NASDAQ:CARA

Cara Therapeutics - CARA Stock Forecast, Price & News

$9.40

+0.52 (+5.86%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $9.00
▼
$9.42
50-Day Range: $8.24
▼
$12.56
52-Week Range: $7.40
▼
$18.93

Volume: 262,625 shs
Average Volume: 385,506 shs
Market Capitalization: $505.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.00

Cara Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 187.2% Upside
$27.00 Price Target
Short Interest: Bearish
16.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.39
Upright™ Environmental Score
News Sentiment: 0.63
Based on 2 Articles This Week
Insider Trading: Selling Shares
$143,604 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.34) to ($0.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

656th out of 1,087 stocks

Pharmaceutical Preparations Industry

313th out of 546 stocks

3.5

Analyst's Opinion

Consensus Rating
Cara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.00, Cara Therapeutics has a forecasted upside of 187.2% from its current price of $9.40.
Amount of Analyst Coverage
Cara Therapeutics has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.99% of the float of Cara Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cara Therapeutics has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Cara Therapeutics does not currently pay a dividend.
Dividend Growth
Cara Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.
Environmental Sustainability
The Environmental Impact score for Cara Therapeutics is -1.39.

2.0

News and Social Media Coverage

News Sentiment
Cara Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Cara Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $143,604.00 in company stock.
Percentage Held by Insiders
Only 3.20% of the stock of Cara Therapeutics is held by insiders.
Percentage Held by Institutions
65.00% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cara Therapeutics are expected to grow in the coming year, from ($1.34) to ($0.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cara Therapeutics is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cara Therapeutics is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cara Therapeutics has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cara Therapeutics (NASDAQ:CARA) Stock

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

September 28, 2022 | barrons.com

Cara Therapeutics Announces Difelikefalin (KORSUVA(R)) Injection New Drug Application Has Been Submitted in Japan

September 28, 2022 | markets.businessinsider.com

Cara Therapeutics Partner Maruishi Submits Difelikefalin NDA In Japan For Pruritus In Hemodialysis

September 26, 2022 | nasdaq.com

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

September 20, 2022 | finance.yahoo.com

Here's Why We're Not Too Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Situation

September 15, 2022 | marketwatch.com

Cara Therapeutics, Inc. (CARA) Appoints Ryan Maynard as Chief Financial Officer

September 8, 2022 | finance.yahoo.com

Cara Therapeutics Presents Results of Oral Difelikefalin In Painful Itching Disorder

September 8, 2022 | finance.yahoo.com

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

September 1, 2022 | seekingalpha.com

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

August 24, 2022 | finance.yahoo.com

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

August 22, 2022 | finance.yahoo.com

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

August 19, 2022 | nasdaq.com

VFMCRP, Cara: Kapruvia Approved In Switzerland To Treat Hemodialysis Patients

August 19, 2022 | finance.yahoo.com

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

August 13, 2022 | nasdaq.com

What You Need To Know About Cara Therapeutics, Inc.'s (NASDAQ:CARA) Investor Composition

August 8, 2022 | seekingalpha.com

Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q2 2022 Results - Earnings Call Transcript

August 8, 2022 | finance.yahoo.com

Cara Therapeutics Reports Second Quarter 2022 Financial Results

August 4, 2022 | finance.yahoo.com

Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?

August 1, 2022 | finance.yahoo.com

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

July 22, 2022 | finance.yahoo.com

Investors in Cara Therapeutics (NASDAQ:CARA) have unfortunately lost 56% over the last three years

July 2, 2022 | morningstar.com

Cara Therapeutics Inc - Stock Chart

June 30, 2022 | seekingalpha.com

Cara reaches main goal in mid-stage trial for pruritus therapy in nerve disorder

June 30, 2022 | msn.com

Cara Therapeutics' Difelikefalin Aces Mid-Stage Study In Patients With Itchy Skin Disorder

June 24, 2022 | seekingalpha.com

Calls A Much Safer Way To Buy Cara Therapeutics

June 5, 2022 | benzinga.com

Cara Therapeutics's Return On Capital Employed Overview

May 10, 2022 | seekingalpha.com

Cara Therapeutics stock soars after Q1 earnings beat, optimism over Korsuva U.S. launch

May 9, 2022 | seekingalpha.com

Cara Therapeutics, Inc. (CARA) CEO Chris Posner on Q1 2022 Results - Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings: 8/08/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CARA
CUSIP: N/A
CIK: 1346830
Web: www.caratherapeutics.com
Phone: (203) 406-3700
Fax: 203-567-1510
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $27.00
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +187.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,440,000.00
Net Margins: -135.72%
Pretax Margin: -135.72%
Return on Equity: -31.47%
Return on Assets: -28.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.32
Quick Ratio: 8.16

Sales & Book Value

Annual Sales: $23.03 million
Price / Sales: 21.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.25 per share
Price / Book: 2.21

Miscellaneous

Outstanding Shares: 53,730,000
Free Float: 52,007,000
Market Cap: $505.06 million
Optionable: Optionable
Beta: 0.95

Key Executives

Mr. Christopher A. Posner (Age 52)
Pres, CEO & Director
Comp: $431.9k

Dr. Derek T. Chalmers D.Sc. (Age 58)
Ph.D., Co-Founder & Sr. Advisor
Comp: $580.93k

Dr. Frédérique Menzaghi (Age 56)
Chief Scientific Officer and Sr. VP of R&D
Comp: $826.94k

Mr. Scott M. Terrillion (Age 59)
Chief Compliance Officer, Gen. Counsel & Corp. Sec.
Comp: $689.63k

Dr. Joana Goncalves (Age 48)
Chief Medical Officer
Comp: $826.77k

Mr. Richard Makara (Age 52)
VP, Head of Accounting, Controller, Principal Financial & Accounting Officer

Dr. Iris Francesconi Ph.D.
Chief Strategy Officer & Head of Investor Relations

Mr. Eric Vandal
Sr. VP of Commercial

Ms. Beth Weinberg
Sr. VP of Regulatory Affairs & QA

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CARA shares.
View CARA analyst ratings or view top-rated stocks.
What is Cara Therapeutics' stock price forecast for 2022?: 3 Wall Street research analysts have issued 12-month price targets for Cara Therapeutics' shares. Their CARA share price forecasts range from $20.00 to $30.00. On average, they expect the company's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 187.2% from the stock's current price.
View analysts price targets for CARA or view top-rated stocks among Wall Street analysts.
How have CARA shares performed in 2022?: Cara Therapeutics' stock was trading at $12.18 at the beginning of the year. Since then, CARA stock has decreased by 22.8% and is now trading at $9.40.
View the best growth stocks for 2022 here.
When is Cara Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CARA earnings forecast.

How were Cara Therapeutics' earnings last quarter?: Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Monday, August, 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.20. The biopharmaceutical company earned $23 million during the quarter, compared to analyst estimates of $21.28 million. Cara Therapeutics had a negative net margin of 135.72% and a negative trailing twelve-month return on equity of 31.47%.
What other stocks do shareholders of Cara Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).
What is Cara Therapeutics' stock symbol?: Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
How do I buy shares of Cara Therapeutics?: Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cara Therapeutics' stock price today?: One share of CARA stock can currently be purchased for approximately $9.40.
How much money does Cara Therapeutics make?: Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $505.02 million and generates $23.03 million in revenue each year. The biopharmaceutical company earns $-88,440,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.
How can I contact Cara Therapeutics?: Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cara Therapeutics - CARA Stock Forecast, Price & News

Cara Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability